Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
In the first 11 months of the year, 1,991 CEOs have announced their departures, up 16% compared to the same timeframe last year.
The offer would put an 83% premium on Soho’s Wednesday closing price and comes a year after it had to close off admissions in three cities.
One ring to rule them all… at least, Oura hopes so. On Thursday, it announced a new $200 million funding round.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
With Trump expected to chase increased oil exports and more drilling in the US, OPEC+’s fear of losing market share looms larger than ever.
Don’t get too excited for cheaper Taylor Swift tickets: The rules just force sellers to present all the extra fees upfront.
Sometimes, markets don’t need breathless buzzwords to get excited. Sometimes, “marginally encouraging” will do. Ask Pfizer shareholders.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
Besides being your one-stop-retail-shop for everything, Walmart would like to be your virtual banker, too.
The Fed may have cracked inflation, but eggflation is proving harder to beat. Unsurprisingly, egg producer stocks are soaring.
After making itself an integral part of the supply chain for generative AI, Nvidia is eyeing other futuristic tech bets.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.